Increased presence of Epstein-Barr virus DNA in ocular fluid samples from HIV negative immunocompromised patients with uveitis

Ongkosuwito, J.V.; van der Lelij, A.; Bruinenberg, M.; Wienesen-van Doorn, M.; Feron, E.J.C.; Hoyng, C.B.; de Keizer, R.J.W.; Klok, A.M.; Kijlstra, A.

Published in:
British journal of ophthalmology

DOI:
10.1136/bjo.82.3.245

Citation for published version (APA):
Ongkosuwito, J. V., van der Lelij, A., Bruinenberg, M., Wienesen-van Doorn, M., Feron, E. J. C., Hoyng, C. B., ... Kijlstra, A. (1998). Increased presence of Epstein-Barr virus DNA in ocular fluid samples from HIV negative immunocompromised patients with uveitis. British journal of ophthalmology, 82, 245-251. https://doi.org/10.1136/bjo.82.3.245
Increased presence of Epstein-Barr virus DNA in ocular fluid samples from HIV negative immunocompromised patients with uveitis

Jenny V Ongkosuwito, Allegonda Van der Lelij, Marcel Bruinenberg, Marian Wienesen-van Doorn, Eric J C Feron, Carel B Hoyng, Rob J W de Keizer, Anne-Marie Klok and Aize Kijlstra


Updated information and services can be found at:
http://bjo.bmjournals.com/cgi/content/full/82/3/245

References
This article cites 26 articles, 7 of which can be accessed free at:
http://bjo.bmjournals.com/cgi/content/full/82/3/245#BIBL

Rapid responses
You can respond to this article at:
http://bjo.bmjournals.com/cgi/eletter-submit/82/3/245

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Notes

To order reprints of this article go to:
http://www.bmjournals.com/cgi/reprintform

To subscribe to British Journal of Ophthalmology go to:
http://www.bmjournals.com/subscriptions/
Increased presence of Epstein–Barr virus DNA in ocular fluid samples from HIV negative immunocompromised patients with uveitis

Jenny V Ongkosuwito, Allegonda Van der Lelij, Marcel Bruinenberg, Marian Wienes-van Doorn, Eric J C Feron, Carel B Hoyng, Rob J W de Keizer, Anne-Marie Klok, Aize Kijlstra

Abstract
Aims—To investigate whether routine testing for Epstein–Barr virus (EBV) is necessary in the examination of a patient with uveitis.

Methods—Intraocular EBV DNA was determined in 183 ocular fluid samples taken from patients with AIDS and uveitis, HIV negative immunocompromised uveitis, acute retinal necrosis, toxoplasma chorioretinitis, intraocular lymphoma, anterior uveitis, and miscellaneous uveitis of unknown cause. In 82 samples from this group of patients paired serum/ocular fluid analysis was performed to detect local antibody production against EBV. Controls (n=46) included ocular fluid samples taken during surgery for diabetic retinopathy, macular pucker, or cataract.

Results—Serum antibody titres to EBV capsid antigen proved to be significantly increased in HIV negative immunocompromised patients with uveitis (p<0.01) compared with controls. Local antibody production revealed only three positive cases out of 82 patients tested, two results were borderline positive and one patient had uveitis caused by VZV. EBV DNA was detected in three out of 46 control ocular fluid samples. In the different uveitis groups EBV DNA was noted, but was not significantly higher than in the controls, except in six out of 11 HIV negative immunocompromised patients (p=0.0008). In four out of these six cases another infectious agent (VZV, HSV, CMV, or Toxoplasma gondii) had previously been identified as the cause of the uveitis.

Conclusions—When comparing various groups of uveitis patients, EBV DNA was found more often in HIV negative immunocompromised patients with uveitis. Testing for EBV does not have to be included in the routine management of patients with uveitis, since indications for an important role of this virus were not found in the pathogenesis of intraocular inflammation.

(Br J Ophthalmol 1998;82:245–251)

The Epstein–Barr virus (EBV) is a member of the herpes virus group. It is an ubiquitous virus and the majority of the adult population has been infected. Individuals are usually infected through saliva during adolescence and display symptoms such as pharyngitis, fever, and lymphadenopathy. The presence of atypical lymphocytes in a blood smear is characteristic of EBV infection, hence its name of “infectious mononucleosis”. It is often a self limiting disease and in most cases infection passes asymptomatically. After primary infection, a large pool of infected B lymphocytes is generated, the number of which gradually reduces once host cell immunity develops. After infection, latent EBV remains present in approximately one of 10^6 B lymphocytes. The humoral immune response is mainly directed against the virus capsid antigen (VCA) and Epstein–Barr nuclear antigen (EBNA) and remains detectable throughout life.

The cellular immune response to EBV is mediated by both cytotoxic and helper T cells. EBV specific T cells can be suppressed or inhibited due to immunodeficiency allowing EBV to reactivate, resulting in proliferation of virus particles, as has been noted in AIDS patients and in patients, who underwent organ transplantation followed by immunosuppressive therapy. EBV has also been associated with the development of Burkitt’s lymphoma in African children, with nasopharyngeal carcinoma in middle aged population in southern China, with lymphoma in immunocompromised patients (AIDS, transplantation patients), and with Hodgkin’s disease.

The role of EBV in the pathogenesis of ocular disease is still controversial. It has been associated with a variety of symptoms, such as conjunctivitis, keratitis, uveitis, choroiditis, and retinitis. In these reports, the diagnosis was based on virus culture from conjunctival or tear samples, or substantiated by serological findings in serum. Only one group has provided evidence of intraocular EBV antibody synthesis in middle aged population patients with bilateral anterior uveitis, and no evidence of infectious mononucleosis. The authors suggested that EBV uveitis might be a new clinical entity.

So far, the evidence for a possible role of EBV in the pathogenesis of uveitis is mainly based on serological evidence. With the availability of more specific laboratory techniques such as polymerase chain reaction (PCR) for the identification of infectious agents during intraocular inflammation we decided to investigate the role of EBV in uveitis and more specifically whether routine testing for this virus is useful in the laboratory examination of a patient with uveitis.

Department of Ophthalmology, Academic Medical Centre, University of Amsterdam, Netherlands J V Ongkosuwito A Kijlstra

Department of Ophthalmo-Immunology, The Netherlands Ophthalmic Research Institute, Netherlands J V Ongkosuwito M Bruinenberg M Wienes-van Doorn A-M Klok A Kijlstra

F C Donders Institute for Ophthalmology, University Hospital Utrecht, Netherlands A Van der Lelij

Eye Hospital Rotterdam, Netherlands E J C Feron

Department of Ophthalmology, University Hospital Nijmegen, Netherlands C B Hoyng

Department of Ophthalmology, University Hospital Leiden, Netherlands R J W de Keizer

Department of Ophthalmology, Hospital of the Free University of Amsterdam, Netherlands A-M Klok

Correspondence to: Jenny V Ongkosuwito, MD, Department of Ophthalmology-Immunology, Netherlands Ophthalmic Research Institute, PO Box 12014, 1100 AC, Amsterdam, Netherlands.

Accepted for publication 10 October 1997

Downloaded from bjo.bmjournals.com on 11 August 2006
findings have not yet pointed to a direct role of EBV in uveitis, but did reveal EBV DNA to be present more often in the eyes of HIV negative immunocompromised patients with uveitis than in the eyes of controls.

**Patients and methods**

In our study, uveitis was diagnosed according to the criteria of the International Uveitis Study Group\(^1\)\(^1\) and the research committee of the American Uveitis Society.\(^1\)\(^2\) Aqueous humour (AH) samples (100–200 µl) were collected by paracentesis for diagnostic purposes. Vitreous fluid (VF) samples (200–1000 µl) were collected during a therapeutic or diagnostic vitrectomy. A venous blood sample was collected and serum was obtained after clotting. In some cases another venous blood sample was taken at the time of paracentesis or vitrectomy, and serum was obtained after clotting. In some cases another venous blood sample was taken during vitreoretinal surgery of 46 patients with uveitis (AIDS, 21; anterior uveitis, 11; acute retinal necrosis, 16; miscellaneous uveitis, 8; HIV negative immunocompromised, 10; intraocular lymphoma, 9; toxoplasma chorioretinitis, 7) Paired EBV antibody analysis was also performed on 20 control samples. From 22 patients we only tested the EBV antibody titre in their serum. These samples were as selectively chosen from our serum bank to match the size of the different groups in which antibodies against EBV were tested. Serum antibody levels against EBV were thus available from 104 patients of the original group of 183.

**Table 1 Detection of intraocular antibody production against EBV and results of PCR for EBV DNA in patients with uveitis**

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Sex M/F</th>
<th>Mean age (years) (range)</th>
<th>EBV DNA present in ocular fluid sample (PCR)</th>
<th>Positive GW† coefficient to EBV</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV negative immunocompromised (n=11)</td>
<td>7/4</td>
<td>44 (14–63)</td>
<td>1/44, 5/72</td>
<td>0/10</td>
</tr>
<tr>
<td>Acute retinal necrosis (n=24)</td>
<td>11/13</td>
<td>49.8 (27–89)</td>
<td>0/11, 1/13</td>
<td>0/2</td>
</tr>
<tr>
<td>Toxoplasma chorioretinitis (n=45)</td>
<td>25/20</td>
<td>36.1 (8–47)</td>
<td>3/28, 1/17</td>
<td>0/7</td>
</tr>
<tr>
<td>Intraocular lymphoma (n=11)</td>
<td>7/4</td>
<td>59.9 (23–75)</td>
<td>0/2, 3/9</td>
<td>0/9</td>
</tr>
<tr>
<td>Anterior uveitis (n=32)</td>
<td>12/20</td>
<td>45.8 (7–83)</td>
<td>3/31, 0/1</td>
<td>0/11</td>
</tr>
<tr>
<td>Miscellaneous uveitis (n=28)</td>
<td>10/18</td>
<td>43.6 (8–79)</td>
<td>3/17, 2/11</td>
<td>0/2</td>
</tr>
<tr>
<td>Controls (n=46)</td>
<td>23/23</td>
<td>59.6 (22–81)</td>
<td>0.9, 3/37</td>
<td>0.0, 0/20</td>
</tr>
<tr>
<td>Total (n=229)</td>
<td>122/107</td>
<td></td>
<td>12/127, 16/102, 9/31</td>
<td>3/102</td>
</tr>
</tbody>
</table>

The data indicate the number of positive samples over total number tested *PBL = peripheral blood leucocyte; †GW = Goldmann-Witmer; ‡p value of aqueous and vitreous samples together calculated by Fisher’s exact test = 0.008.
5' primer: CTC TGG TAG TGA TTT GGA CC nucleotide location 781
3' primer: GTG AAG TCA CAA ACA AGC CC nucleotide location 1001.

The expected size of the amplified product was 240 base pairs.

To prevent carryover contamination with PCR products from previous reactions we used uracil DNA glycosylase and dNTPs (dTTP was replaced by dUTP) according to Longo et al. Other precautions included the use of filtertips and separate rooms for isolating DNA, preparing the PCR mixture and running the PCR.

The PCR mixture (50 µl) contained: 50 mM KCl, 10 mM TRIS (pH 8.3), 10 µg of bovine serum albumin, 2.0 mM MgCl₂, 0.4 pmol of each primer, 0.2 pmol of dUTP (Sphaero Q, Leiden), 0.2 pmol each of dGTP, dATP, dCTP (Pharmacia), 1 unit of Ampli-Taq DNA Polymerase (Perkin Elmer), 0.1 unit of uracil DNA glycosilase (Life Technologies), 5 µl of plasmid containing target DNA, was varicella zoster virus, was cytomegalovirus, 20 copies; herpes simplex virus type 1, 20 copies; varicella zoster virus, 20 copies; cytomegalovirus, 20 copies; herpes simplex virus type 1, 35 copies; Epstein–Barr virus: 20 copies; and toxoplasma gondii, 30 copies.

The presence of DNA in the various isolates was verified using a PCR for β globin as described elsewhere.

**SEROLOGY**

Determination of intraocular IgG antibody production against CMV, HSV, VZV, EBV, and *Toxoplasma gondii* was performed according to techniques described elsewhere. IgG antibodies detected in the immunofluorescence assay for EBV (Gull Laboratories, Inc, Salt Lake City, UT, USA) are mainly directed to the EBV capsid antigen. Local intraocular antibody production was considered to be present when the Goldmann–Witmer (GW) coefficient was higher than 3.0.

During data analysis a cut off value of 1:512 was taken to indicate an increased serology.

**STATISTICS**

Statistical analysis of the data was performed using the χ² test and the Fisher's exact test. Cumulation of type I errors was corrected for by taking α=0.01.

**RESULTS**

To evaluate the role of EBV in the pathogenesis of uveitis, the serum IgG antibody level to EBV CA (capsid antigen) was tested in uveitis patients and controls (Fig 1). When a cut off value of 1:512 was taken, the serum titres were significantly increased compared with controls in the HIV negative immunocompromised patients (p=0.002). All HIV negative immunocompromised patients (n=11) had a titre ≥ 1:512 to EBV compared with eight out of 18 controls. All other groups of uveitis patients tested did not have significantly raised EBV titres in their blood compared with controls.

To further investigate the role of EBV in uveitis we also investigated local intraocular antibody production against this virus. Local EBV antibody production was not found in the controls tested (n=20; diabetic retinopathy, nine; cataract, six; vitreous haemorrhage, three; retinal detachment, one; and epiretinal membrane, one). On the other hand, local antibody production to EBV could be detected in three out of 82 uveitis samples (Table 1). Of these three positive patients one (female, 26 years, GW coefficient for EBV 3.8) belonged to the HIV negative immunocompromised patients and had a clinical diagnosis of choroiditis.

![Figure 1](image_url)
A previously taken ocular fluid sample had a positive result for rubicin, vincristine, prednisone; NHL = non-Hodgkin’s lymphoma; BM = bone marrow. AH = aqueous humour; VF = vitreous fluid; CsA = cyclosporin A; Aza = azathioprine; Pred = prednisone; Ara C = cytarabine; CHOPP = cyclophosphamide, doxorubicin, vincristine, prednisone; NHL = non-Hodgkin’s lymphoma; BM = bone marrow.

Table 2: Clinical details and laboratory test results in the group of HIV negative immunocompromised patients with uveitis

<table>
<thead>
<tr>
<th>Patient no, sex, age (years)</th>
<th>Diagnosis</th>
<th>Ocular diagnosis</th>
<th>Sample</th>
<th>Positive GW</th>
<th>Immunosuppressive medication</th>
<th>Positive PCR for</th>
</tr>
</thead>
<tbody>
<tr>
<td>1, F, 27</td>
<td>SLE</td>
<td>CMV retinitis</td>
<td>VF</td>
<td>CMV=4</td>
<td>Aza</td>
<td>CMV/EBV</td>
</tr>
<tr>
<td>2, M, 47</td>
<td>Non-Hodgkin’s lymphoma</td>
<td>CMV retinitis</td>
<td>VF</td>
<td>CMV=7.2</td>
<td>CHOPP</td>
<td>None</td>
</tr>
<tr>
<td>3, M, 62</td>
<td>Heart transplantation</td>
<td>CMV retinitis</td>
<td>VF</td>
<td>CMV=4.6</td>
<td>CsA/pred/Aza</td>
<td>EBV</td>
</tr>
<tr>
<td>4, M, 63</td>
<td>Heart transplantation</td>
<td>Toxoplasma chorioretinitis</td>
<td>VF</td>
<td>Toxoa=3.0</td>
<td>CsA/pred/Aza</td>
<td>Toxo/EBV</td>
</tr>
<tr>
<td>5, M, 55</td>
<td>Heart transplantation</td>
<td>Toxoplasma chorioretinitis</td>
<td>AH</td>
<td>Toxoa=3.1</td>
<td>CsA/Aza</td>
<td>Toxo</td>
</tr>
<tr>
<td>6, F, 35</td>
<td>NHL (BM transplantation)</td>
<td>Toxoplasma chorioretinitis</td>
<td>AH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7, M, 59</td>
<td>Kidney transplantation</td>
<td>VZV acute retinal necrosis</td>
<td>AH</td>
<td></td>
<td>None/dexamethasone</td>
<td>VZV</td>
</tr>
<tr>
<td>8, M, 14</td>
<td>Leukaemia</td>
<td>VZV acute retinal necrosis</td>
<td>VF</td>
<td>VZV=7.1</td>
<td>Ara C/dacarbazine</td>
<td>EBV</td>
</tr>
<tr>
<td>9, F, 26</td>
<td>Kidney transplantation</td>
<td>Chorioretinitis</td>
<td>AH</td>
<td>EBV=3.8</td>
<td>Aza/pred</td>
<td>None</td>
</tr>
<tr>
<td>10, M, 42</td>
<td>Hodgkin’s lymphoma</td>
<td>Anterior uveitis</td>
<td>AH</td>
<td></td>
<td>Not mentioned</td>
<td>EBV</td>
</tr>
<tr>
<td>11, F, 55</td>
<td>Mammacarcinoma</td>
<td>Uveitis</td>
<td>VF</td>
<td></td>
<td>Dexamethasone</td>
<td>None</td>
</tr>
</tbody>
</table>

AH = aqueous humour; VF = vitreous fluid; CsA = cyclosporin A; Aza = azathioprine; Pred = prednisone; Ara C = cytarabine; CHOPP = cyclophosphamide, doxorubicin, vincristine, prednisone; NHL = non-Hodgkin’s lymphoma; BM = bone marrow.

* A previously taken ocular fluid sample had a positive result for Toxoplasma DNA.
Of the two patients, who were exclusively positive for intraocular EBV DNA one was clinically diagnosed as having toxoplasma chorioretinitis and the other having anterior uveitis with unknown cause. The details of these patients were as follows.

**Patient 1** (male, 63 years) who had received a heart transplant 6 months earlier, was diagnosed as having toxoplasma chorioretinitis. Ocular fluid samples taken at that time confirmed the diagnosis: local antibody production against *T gondii* (GW coefficient 7.7) and *T gondii* DNA could be detected. After 8 weeks, maintenance therapy (pyrimethamine and folinic acid) was instituted and visual acuity was restored from 3/60 to 1.0 in about 3 months. Despite the maintenance therapy, the visual acuity decreased to 0.25 in another 3 months, due to vitreous opacities. The previous toxoplasma chorioretinitis scars were completely quiet. A diagnostic pars plana vitrectomy was performed, since intraocular lymphoma was suspected. At that time his general medication consisted of prednisone, cyclosporine, and azathioprine among others. Intraocular lymphoma could not be confirmed in the vitreous fluid by cytological examination. A negative GW coefficient (<3) and PCR test did not support a diagnosis of active toxoplasma chorioretinitis. PCR tests for CMV, HSV-1, VZV, *T gondii* were all negative but the PCR test for EBV was positive.

**Patient 10** (male, 42 years) suffering from Hodgkin’s disease, had a clinical diagnosis of anterior uveitis. No other infectious agents were detectable in his ocular fluid sample. This patient had a very high titre to EBV (≥1:512,000 in serum). In the HIV positive immunocompromised patient group three out of 32 patients had EBV DNA in their eye (not significantly different compared with controls). In these three cases another infectious cause was proved—CMV, HSV, and *T gondii*, respectively.

As already mentioned above, none of the patients with a positive Goldmann–Witmer coefficient against EBV had EBV DNA in their eyes. Furthermore, no association could be found between serum EBV antibody levels and a positive EBV DNA result in the ocular fluid samples.

To investigate whether the presence of EBV DNA in the eye is caused by “overflow” out of the peripheral circulation, PCR was done on serum and PBL samples. Analysis of EBV DNA in serum (11 samples from the HIV negative immunocompromised patient group) revealed only one positive sample, patient 10, who also had a very high level of EBV CA antibody titre (≥1:512,000) and EBV DNA in his eye. In this patient the presence of EBV DNA in the eye could be due to overflow from the circulation.

PBL samples were not routinely investigated during the examination of patients with uveitis, and were therefore available in only 31 of the 183 patients included in this study. DNA was isolated from the samples and tested for the presence of EBV DNA. EBV DNA was found in nine out of 31 PBL samples tested (Table 1). In this selected group of 31, five cases had EBV DNA in their eye, of whom two were also positive in their PBL sample. One of these patients was from the HIV positive patient group and one was from the HIV negative patient group (patient 5, toxoplasma chorioretinitis).

To investigate if the positive signal of the ocular fluid sample was caused by “overflow” from the peripheral blood circulation, the ocular fluid and PBL sample from these two patients were tested for EBV DNA in the same PCR. The same was done for β globin DNA to correct for the amount of cells in the ocular fluid sample and the PBL sample. Although the signals for β globin DNA were almost the same, the signal for EBV DNA in both ocular fluid samples was clearly more positive than in the PBL samples (Fig 2). This indicates local proliferation of the virus in the eyes of these patients.

**Discussion**

We investigated the role of EBV testing in the management of uveitis in a number of patient groups and observed that only the HIV negative immunocompromised patients with uveitis had a higher incidence of EBV DNA in their ocular fluids than the controls. EBV DNA was found in 54% of HIV negative immunocompromised patients compared with 9% in AIDS patients with uveitis and this latter group was not different from controls (8%). Systemic reactivation of EBV has been described for the HIV negative and HIV positive immunocompromised patients groups, but to our knowledge no comparative study has been reported concerning viral load in patients with acquired immunodeficiencies. HIV negative immunocompromised patients differ from HIV positive patients in the mechanisms responsible for immunosuppression. Immunosuppression due to medication (chemotherapy, immunosuppressive drugs) may follow another mechanism than immunosuppression due to infection with HIV.

To our knowledge, this is the first report investigating the presence of intraocular EBV DNA and intraocular EBV antibody production in a large group of uveitis patients. Analysis of local antibody production against EBV only revealed three positive cases out of 82 patients tested, whereby two results were borderline positive. The remaining positive patient also had a GW coefficient for VZV. Whether this was due to a double infection or cross reactivity between these two herpes viruses remains an open question. From these
results we have concluded that routine testing for intraocular antibody production in a general uveitis population has no additional value in the examination of these patients. Usui and Sakai\(^2\) described a typical clinical picture of anterior uveitis in these patients whereby intraocular EBV antibody production was found. We did test a small group of patients with anterior uveitis, but none showed evidence of EBV infection which may be due to the fact that our group of patients did not contain individuals with the entity as described by Usui and Sakai.

Analysis of EBV DNA in our patients with uveitis also did not support a direct role for this virus in the pathogenesis of the intraocular inflammation in these cases. This conclusion is based on the fact that ocular viral DNA was found in 8% of “non-uveitic” control samples, but only in 5–10% of uveitis cases with known “other” infective cause such as T. gondii, VZV, CMV, or HSV. In view of these findings a positive EBV PCR test result in our patient group with miscellaneous uveitis with an unknown cause was difficult to interpret.

Many investigators have been intrigued by the possible role of EBV in the pathogenesis of ocular inflammation.\(^5\) The main problem in establishing direct proof is the ubiquitous presence of this virus. Until now, the evidence was mainly based on serological findings and not supported by viral culture or molecular biological analysis.

A recent study described the presence of EBV DNA in 50% of aqueous and 20% of vitreous samples taken from normal cadaveric eyes.\(^3\) We only found the EBV genome in 8% of the vitreous and in none of the aqueous samples taken from “non” uveitic eyes. The great difference between our results and those published by Chodosh et al.\(^7\) is probably due to the sensitivity of the technique because they used Southern blotting and hybridisation with radioactive probes, whereas we only scored amplified products after electrophoresis and ethidium bromide staining of the agarose gel.

The increased presence of EBV in HIV negative immunocompromised patients could be due to either local reactivation or spreading of reactivated systemic EBV to various organs and tissues including the eye. B lymphocytes and various epithelial tissues are known to harbour latent EBV but, as yet, no intraocular site harvesting latent EBV has been reported. The local reactivation of EBV in this group of patients is probably due to the fact that they were severely immunocompromised as a result of the administration of various immunosuppressive drugs.

From our investigations on peripheral blood leucocytes and ocular fluid samples, we conclude that a diagnosis of intraocular lymphoma was not due to either local reactivation of intraocular EBV or spreading of reactivated EBV to various organs and tissues. From the fact that the signal in the eye was clearly more positive than in the PBLs compared with a similar β globin signal for both samples, we conclude that in these patients the presence of EBV in the eye may have been caused by a local reactivation. Further evidence of local reactivation should include mRNA analysis of EBV genes involved in reactivation of this virus.\(^24\)

Detection of EBV DNA in other body fluids, such as cerebrospinal fluid, has been shown to predict the occurrence of primary central nervous system lymphoma in AIDS patients.\(^28\) Whether the detection of EBV DNA in intraocular fluids may also predict the presence of intraocular lymphomas in immunocompromised patients remains to be investigated. In series of immunocompromised patients we investigated so far, no intraocular lymphomas were observed.

Whether the presence of concomitant EBV influences the course of intraocular inflammation due to other causes such as Toxoplasmosis, VZV, HSV or CMV remains speculative. EBV is known to produce an active homologue of interleukin 10 and may also activate B lymphocytes to produce this immunosuppressive cytokine.\(^25\)\(^26\)

Our current hypothesis is that EBV is not a direct cause of uveitis, but that it may well play a role as a secondary factor in the pathogenesis of uveitis. Analysis of virally expressed immunomodulatory factors (for example, a homologue to human IL-10) in the intraocular environment may improve our knowledge of this issue.


